Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Controlled Trials to Assess Approved SARS-CoV-2 Vaccines in Immunocompromised Patients: A Master Protocol for the Set-up of a Swiss Cohorts Based Trial Platform

NCT04805125 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.

NCT NCT04805125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04805125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Controlled Trials to Assess Approved SARS-CoV-2 Vaccines in Immunocompromised Patients: A Master Protocol for the Set-up of a Swiss Cohorts Based Trial Platform
Lead sponsor
University Hospital, Basel, Switzerland
Phase
Phase 3
Overall status
Completed
Start date
April 19, 2021
Completion date
September 23, 2023
Enrollment
610 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

immunocompromised patients